EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects

Yun Liu iD, Xiaoning Chen, Huimin Tang iD, Fan Jiang, Yaqin Tang iD, Huijuan Zhu iD, Yanping Du iD, Hongjie Qian iD, Shuyun Liu iD, Xiaoshu Sun, Bin Zan, Yuexia Zeng und 4 weitere

Clinical and Translational Science · 2025-03 · 18 (3)

DOI: 10.1111/cts.70179 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 10.03.2025. Verfasst von Yun Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Sulfonamides, Antifibrotic Agents, Pyridones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SC1011 (sufenidone) is a novel pyridone derivative with therapeutic potential for idiopathic pulmonary fibrosis (IPF). Two Phase 1 studies evaluated the safety and pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SC1011 immediate‐release (IR) and modified‐release (MR) oral formulations in healthy adult subjects. In Phase 1a, subjects were randomized to receive oral SC1011 IR or placebo in SAD (50 mg‐300 mg) or MAD (100 mg and 200 mg) twice daily for 7 days. The Phase 1b study consisted of three treatment groups that received 100, 150, or 200 mg SC1011 MR twice daily for 7 days. SC1011 IR was absorbed rapidly (mean time to maximum concentration, T max ≤ 1 h) and eliminated rapidly (mean terminal half‐life, t 1/2 : 1.23–2.64 h) following 50–300 mg single‐dose administrations. Reduced maximum plasma concentration (C max ), delayed T max , and comparable total exposure were observed with the MR formulation compared with the IR formulation. Both formulations demonstrated dose‐proportional pharmacokinetics at the applied dose ranges, and no obvious accumulation of systemic exposure was observed upon repeated administration. All treatment‐emergent adverse events (TEAEs) with both formulations were mild or moderate in severity, and gastrointestinal reactions were the most frequently reported TEAEs. The tolerability of SC1011 was markedly improved with the MR formulation. Exposure–adverse event (AE) analysis with the most frequent AEs identified C max rather than total exposure as a good predictor of AEs. Compared to the IR formulation, SC1011 MR demonstrated improved exposure and tolerability, supporting its further development in patients with IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesAntifibrotic AgentsPyridonesHumansMaleAdultFemaleMiddle AgedHealthy VolunteersAdministration, OralYoung AdultDouble-Blind MethodDose-Response Relationship, DrugHalf-LifeDelayed-Action PreparationsIdiopathic Pulmonary FibrosisDrug Administration Schedule

Stichwörter der Autor:innen

a novel pyridone derivativeexposure–adverse event analysisformulation optimizationidiopathic pulmonary fibrosis

Substanzen

SulfonamidesAntifibrotic AgentsPyridonesDelayed-Action Preparations

Autor:innen und Institutionen

  • Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
  • Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai Engineering Research Center, Shanghai, China.
  • Guangzhou Joyo Pharmatech Co., Ltd., Building C, Yunsheng Science Park, Guangzhou, Guangdong, China.
  • The First Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, Guangdong, China.
  • Hangzhou Chengbang Pharmaceutical Technology Co., Ltd., Hangzhou, Zhejiang, China.

ORCID-Profile: Yun Liu, Huimin Tang, Yaqin Tang, Huijuan Zhu, Yanping Du, Hongjie Qian, Shuyun Liu, Zhongqi Yang

Zitieren

APA

Liu, Y., Chen, X., Tang, H., Jiang, F., Tang, Y., Zhu, H., Du, Y., Qian, H., Liu, S., Sun, X., Zan, B., Zeng, Y., Li, Y., Ge, Z., Li, Y., & Yang, Z. (2025). Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects. Clinical and Translational Science, 18(3). https://doi.org/10.1111/cts.70179

Vancouver

Liu Y, Chen X, Tang H, Jiang F, Tang Y, Zhu H, et al. Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects. Clinical and Translational Science. 2025;18(3). doi:10.1111/cts.70179

BibTeX
@article{Liu2025,
  author = {Liu, Yun and Chen, Xiaoning and Tang, Huimin and Jiang, Fan and Tang, Yaqin and Zhu, Huijuan and Du, Yanping and Qian, Hongjie and Liu, Shuyun and Sun, Xiaoshu and Zan, Bin and Zeng, Yuexia and Li, Yun and Ge, Zhen and Li, Yongguo and Yang, Zhongqi},
  title = {Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {3},
  doi = {10.1111/cts.70179}
}
Kostenlos starten →